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Challenges and opportunities in designing
clinical trials for neuromyelitis optica
ABSTRACT
Current management of neuromyelitis optica (NMO) is noncurative and only partially effective.
Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment.
Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of
NMO has impeded clinical trials for this disease. However, a diagnostic biomarker and recognition
of a wider spectrum of NMO presentations has expanded the patient population fromwhich study
candidates might be recruited. Emerging insights into the pathogenesis of NMO have provided
rationale for exploring new therapeutic targets. Academic, pharmaceutical, and regulatory com-
munities are increasingly interested in meeting the unmet needs of patients with NMO. Clinical
trials powered to yield unambiguous outcomes and designed to facilitate rapid evaluation of an
expanding pipeline of experimental agents are needed. NMO-related disability occurs incremen-
tally as a result of attacks; thus, limiting attack frequency and severity are critical treatment
goals. Yet, the severity of NMO and perception that currently available agents are effective pose
challenges to study design. We propose strategies for NMO clinical trials to evaluate agents
targeting recovery from acute attacks and prevention of relapses, the 2 primary goals of NMO
treatment. Aligning the interests of all stakeholders is an essential step to this end. Neurology®
2015;84:1805–1815
GLOSSARY
AQP4 5 aquaporin-4; IgG 5 immunoglobulin G; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; PLEX 5 plasma
exchange.
Neuromyelitis optica (NMO) is a frequently relapsing inflammatory disease with a predilection
for optic nerves and spinal cord. The specific biomarker aquaporin-4 (AQP4)–immunoglobulin
G (IgG) is detected in most patients,1 but assays for AQP4-IgG vary in sensitivity and speci-
ficity.2 In vivo and in vitro studies and favorable response to plasma exchange (PLEX) suggest
that AQP4-IgG is pathogenic.3–6 Some patients with NMOmay develop symptoms implicating
involvement of other CNS regions such as the area postrema and hypothalamus.7,8 Others have
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limited variants of NMO (e.g., recurrent optic
neuritis or recurrent myelitis). Such patients are
collectively referred to as having NMO spec-
trum disorders. In seropositive patients, a con-
fident diagnosis can be made after a single
clinical event. While AQP4-IgG detection facil-
itates diagnosis and predicts relapse,9 an impor-
tant proportion of cases are seronegative.10,11
Acute NMO attacks are generally more
severe than those of multiple sclerosis (MS)
and may be fatal.12,13 Mortality estimates have
improved from 30% at 5 years,12 to 9% at 6
years.13 Unlike MS, disability in NMO occurs
as cumulative sequelae of attacks rather than
during a secondary progressive phase.14
Thus, minimizing the frequency and severity
of attacks is a primary therapeutic goal. IV
corticosteroids and, in refractory cases, PLEX
are currently used to treat acute attacks. Immu-
nosuppressive agents (e.g., azathioprine,
mycophenolate mofetil, rituximab, and corti-
costeroids) are prescribed to reduce attack
frequency, based on small, uncontrolled stud-
ies.15–17 These agents are collectively referred
to as “empiric” treatments herein, to avoid
any suggestion that a standard of NMO ther-
apy has been established.
Several obstacles have historically limited
clinical trials in NMO. However, these bar-
riers are now mitigated by important advances
that increase the feasibility of informative trials
(table 1). An increasing number of therapeutic
candidates, including those repurposed for
evaluation in NMO, and emerging candidates
specific to AQP4 (e.g., aquaporumab),18 create
an immediate need for definitive NMO clini-
cal trials. Promising repurposed agents include
the following:
1. Rituximab (anti-CD20 monoclonal antibody tar-
geting B cells)19,20
2. Eculizumab (anti-C5 monoclonal antibody target-
ing complement)21
3. Tocilizumab (anti-IL-6R monoclonal antibody
targeting T- and B-cell activation, Th17 differen-
tiation, and plasmablast survival)22–24
Clinical trial templates developed for MS are
not directly applicable to NMO (table 2).
Herein, we review issues pertinent to clinical
trial development in NMObased on discussions
among clinicians, researchers, industry partners,
and patients at research-focused meetings of the
Guthy-Jackson Charitable Foundation. Key
concepts were further refined by all coauthors,
including one serving in a regulatory capacity.
OVERARCHING CONCEPTS FOR NMO CLINICAL
TRIAL DESIGN No drug or treatment has been
proven to be safe and effective in NMO in random-
ized, controlled studies, and none has received regula-
tory approval.
Opinions vary widely among investigators regard-
ing ethics of placebo-controlled studies for mainte-
nance treatment of NMO. NMO-associated
transverse myelitis and optic neuritis attacks can
result in devastating neurologic consequences.12,13
Moreover, retrospective analyses suggest that current
empiric therapies may be moderately effective.20,25,26
However, ascertainment bias and biases inherent in
treatment discontinuation and reporting of attacks in
retrospective studies preclude conclusions regarding
efficacy of any currently used agent. Furthermore,
rigorous studies frequently contradict theoretical ben-
efit27 or reveal unexpected toxicity,28 especially when
agents are tested in combination.29 Some investigators
and regulatory agencies regard the evidence support-
ing effectiveness of current empiric treatments suffi-
ciently inadequate that placebo-controlled studies in
NMO are justified for several reasons, including:
1. Noninferiority studies require an established stan-
dard of treatment that currently does not exist.
2. NMO clinical trials must address safety as well as
efficacy both for acute and chronic exposure, con-
sidering that long-term therapy is likely necessary.
3. Sensitive and meaningful NMO-customized out-
comes measures are needed to inform treatment.
Attacks, rather than neurodegeneration, are the
principal contributors to NMO-related disability.14
Thus, frequency and severity of attacks are the most
suitable primary endpoints in NMO clinical trials.
Validated criteria, including imaging evidence, that
define specific signs or symptoms of an acute attack
are necessary for optimal trial design. Whether
nonattack-related effects of the disease (e.g., changes
in cognitive function, behavior, or other neurologic
functions) occur in NMO is uncertain. Likewise,
laboratory-based biomarkers reflecting or predicting
NMO attack frequency, severity, or therapeutic effi-
cacy must be validated before consideration as surro-
gate outcomes.30–34 Poor cross-sectional correlation of
AQP4 autoantibody titers with NMO disease activity
and severity exemplifies this issue. Longitudinal
assessment of titers within individuals may be more
promising than between individuals, although this
has not been adequately explored.35,36 Similar
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considerations apply to serum cytokine levels, immune
cell profiles,34 or surrogates of tissue-specific injury
(e.g., CSF glial fibrillary astrocytic protein37). CSF pa-
rameters are difficult to measure serially, and MRI
signals are highly variable among individuals. Brain
MRI abnormalities in NMO occur in selective regions,
are difficult to quantify, and have inconsistent associ-
ation with clinical disability. Changes in retinal nerve
fiber layer thickness over time, as measured by optical
coherence tomography, are more striking in NMO
than in MS.38 However, some patients with NMO
spectrum disorders do not have optic nerve events,
and changes in optical coherence tomography are typ-
ically delayed after acute events.
SPECIFIC CONCEPTS FOR NMO CLINICAL TRIAL
DESIGN Two clinical situations represent major
opportunities to mitigate worsening of the disease:
(1) treatment of acute events, and (2) maintenance
treatment (relapse prevention).
Acute event (onset or relapse). Synopsis. The key inter-
acting elements in acute NMO lesions are
Table 1 Obstacles and advances influencing development of clinical trials for NMO
Obstacles Advances
Rarity Improved diagnosis
Prevalence estimated to be 1–5/100,00048,49 Increased sensitivity, attributable to novel biomarker, AQP4-IgG
1%–5% of demyelinating diseases in western countries; .50% in some Asian
countries50
Appreciation of NMO spectrum disorder with resulting expansion of
pool of eligible patients
Diagnostic uncertainty Increased specificity of diagnosis
Mimics: MS, neurosarcoidosis, paraneoplastic disorders; mitochondrial
encephalomyelopathies
More sensitive and specific assays for AQP4-IgG
Confusing nomenclature: Devic disease; opticospinal MS; syndromic nomenclature
(e.g., recurrent transverse myelitis)
Improved ability to distinguish between NMO and MS
Heterogeneity Greater availability of natural history data13 and data reflecting impact
of maintenance therapy
AQP4-IgG seropositive vs seronegative50 Identification of relevant therapeutic targets51,52
Monophasic vs relapsing12 AQP4 antibodies. Protective antibodies engineered by protein
modification to abrogate complement- and cell-dependent
cytotoxicity18
Variability in sensitivity and specificity in AQP4-IgG assays2 Specific B-cell population markers and B-cell/plasmablast survival
factors (IL-6)22,23,34
Challenges of placebo-controlled design Downstream effectors of AQP4-IgG interaction with AQP4, including
complement,21 neutrophils, and eosinophils53,54
Risk of severe and irreversible disability from attacks Th17 pathway55
Generally accepted “standard treatments” for attacks and preventative treatments,15
despite lack of rigorous proof in NMO-dedicated placebo-controlled studies
Variable and unpredictable disease course
Heterogeneous risk of events following enrollment; not easily predicted at current time
Changing prognosis with changes in diagnostic criteria, early recognition, and treatment
“Benign” cases of NMO45
Lack of prospectively validated outcome measures designed for use in NMO
Different evolution and more limited involvement of CNS than MS; Expanded Disability
Status Scale and related functional systems not immediately translatable
Lack of imaging or laboratory biomarkers reflecting disease activity and response to
therapy
Pathogenesis incompletely understood; optimum targets unclear
Complexities of delivery of novel antigen-directed therapeutics18
Achieving adequate concentrations and sufficient half-life to provide protection at site of
target antigen
Abbreviations: AQP4 5 aquaporin-4; IgG 5 immunoglobulin G; IL-6 5 interleukin 6; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica.
Table 2 Selected features differentiating NMO from MS
Progressive disease uncommon; disability accumulates as a result of attacks14
Attacks are more severe in NMO
Absence of informative MRI changes that serve as primary outcome of proof-of-concept phase II
clinical trials in MS56
Predilection of specific regions of CNS in NMO (optic nerve, spinal cord, area postrema, and
circumventricular organs)
Abbreviations: MS 5 multiple sclerosis; NMO 5 neuromyelitis optica.
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AQP4-IgG, AQP4, complement, and granulocytes.
Typically, acute events are treated with high-dose
pulse corticosteroids, and with PLEX in refractory
cases. The following considerations apply to clinical
trials of treatment of acute NMO episodes.
Inclusion/exclusion criteria. An issue common to all
potential NMO clinical trials is whether participation
should be confined to AQP4-IgG–seropositive indi-
viduals (table 3). Restricting enrollment to seroposi-
tive patients would enhance cohort homogeneity and
diagnostic certainty, excluding NMOmimics, such as
sarcoidosis or paraneoplastic disorders. The majority
of potential study participants are seropositive. How-
ever, current serologic assays have imperfect sensitiv-
ity and may not predict treatment response.39 To
address potential for differential efficacy, patients
may need to be randomized based on serostatus.40
Clinical trial designs.The potential for severe and irre-
versible morbidity during acute NMO attack is partic-
ularly relevant in evaluating the acceptability and
ethical correctness of trial design (Table 3 and figure 1).
Single agent vs placebo. Randomized placebo-
controlled trials established that corticosteroids
shorten recovery of acute optic neuritis and MS
relapses (figure 1A).41,42 Although no comparable
studies exist in NMO, widespread corticosteroid use
and acceptable short-term adverse event profile make
it difficult to prohibit their use. Following treatment
with corticosteroids, subjects are randomized to an
experimental drug vs placebo, either after or concur-
rent to their treatment with corticosteroid therapy.
PLEX was superior to sham pheresis in a controlled
study of acute, severe attacks of CNS demyelinating
disease that failed corticosteroid treatment; that study
included 2 patients with NMO.43 Subsequent uncon-
trolled prospective and retrospective clinical studies in
patients with NMO also reported favorable out-
comes. In the only sham-controlled study, patients
failing the initial randomized treatment crossed over
to the comparator, allowing both intra- and interin-
dividual comparisons of PLEX efficacy with sham.
The opportunity for favorable outcomes may decline
as the interval from treatment initiation lengthens
and neurologic injury becomes irreversible; therefore,
it is necessary to consider the sequence of treatment in
the analysis. Crossover of subjects who do not
improve is also a risk mitigation and recruitment facil-
itation strategy by guaranteeing access to the active
Table 3 Pros and cons of design issues in NMO clinical trials
Study measure Pro Con
Study design
Placebo control Scientifically rigorous; required sample size smaller assuming current
empiric therapies are effective; fewer total attacks required assuming
current therapies effective
Potential for greater risk of attacks in placebo group if current empiric
therapies are efficacious and withheld; addresses superiority to
placebo, not to current empiric regimens; risk of attack for a given
patient in control arm potentially greater than in treatment arm
Placebo control as
add-on to standard
therapy
Rigorous, while allowing for potential benefits of empiric therapy Incomplete consensus on details of empiric therapy makes uniformity
difficult; empiric therapy may have failed in a patient who is then
continued on the same regimen; difficult to disentangle effects of
experimental and empiric therapy; may reduce event number and
necessitate a larger sample size or a longer study than if compared
with placebo; potential additive toxicity of experimental and empiric
treatment
Comparison to
empiric therapy
May mitigate risk to individual patient and enhance acceptability or
enrollment; addresses whether new therapy offers incremental
benefit to current practice
Empiric therapy not established to be efficacious; superiority required;
if the standard therapy is effective, a larger sample size or longer study
may be necessary than if compared with placebo; specified standard
therapy may be ineffective or even harmful; may be unacceptable for
regulatory approval in some jurisdictions
Inclusion criteria
AQP4-IgG1 Enhanced homogeneity; majority of patients are AQP4-IgG1 Assay incompletely sensitive; some may seroconvert in follow-up;
excludes 30% of patients classified as NMO spectrum disorder and
thereby prolongs enrollment; effects of treatment on AQP4-IgG
seronegative subjects not addressed; may require licensing of
AQP4-IgG as codiagnostic and may restrict access after approval to
patients who are AQP4-IgG seronegative
Endpoint
Time to first event Enables early exit in treatment failure Latency to onset of action uncertain and treatment failure declaration
may be premature; loss of potential information from each patient;
attack definition may not be sufficiently rigorous to distinguish true
from pseudo-attacks
Annualized relapse
rate
More information for each enrolled patient because all observed
attacks used in analysis
Early withdrawals pose major problem for study power and
interpretability of results
Composite of
relapse severity
and frequency
May add additional important information that could be an important
aspect in evaluation of drug efficacy
No validated method exists to evaluate attack severity
Abbreviations: AQP4 5 aquaporin-4; IgG 5 immunoglobulin G; NMO 5 neuromyelitis optica.
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treatment in either the first or second treatment
phase.
Add-on to corticosteroid treatment. A randomized,
placebo-controlled study of an add-on therapy may
be appropriate for agents with theoretical additive
or synergistic benefit (e.g., addition of a granulocyte
inhibitor or complement inhibitor to pulse corticoste-
roid treatment) (figure 1B). If combination therapy
proves efficacious, follow-up studies would be neces-
sary to evaluate superiority of the experimental drug
as a single agent.
Outcome measures. Evaluation of attack-specific out-
comes requires that neurologic deficits be assessed and
recovery quantified with pertinent impairment scales.
An integrated estimate of recovery (e.g., mild, moder-
ate, marked) could be pooled regardless of the site of
the attack. The proportion of patients who achieve
these levels of recovery could be compared across
treatments.43 Thus, patients having a variety of neu-
rologic deficits (e.g., visual, motor, or sensory) could
be included in a single study. Recovery of the patient-
specific “targeted neurologic deficit” is a focused and
relevant outcome43 and is typically assessed within 2
to 4 weeks after an event. Favorable treatment-related
outcomes generally occur rapidly but delayed benefit
is also of interest.
Attack prevention. Synopsis. Attack prevention studies
are typically offered to patients in remission who may
more favorably consider participation in a placebo-
controlled trial. Current preventive regimens are
nonspecific, and include low-dose oral corticosteroids
and lymphocyte-directed immunosuppressants.
Newer strategies may target upstream mechanisms
involved in AQP4-IgG generation, such as
specific plasmablast expansion,34 CNS trafficking,
and autoreactive T-cell activation.44 The following
considerations are relevant to clinical trials
evaluating maintenance treatments.
Inclusion/exclusion criteria. Restricting enrollment to
seropositive individuals was discussed in the context
of acute disease (table 3). Comorbidities, such as infec-
tions, immunodeficiencies, and agent-specific risk fac-
tors, typically exclude participation. A minimum level
of recent disease activity is required to exclude subjects
with quiescent disease. However, targeting patients
with high levels of recent disease activity for enrollment
to enhance study power may limit the ability to gener-
alize results. Furthermore, the attack frequency may
regress to a lower mean event rate on study.
Clinical trial designs. Three potential clinical trial
strategies are considered for phase IIb/III mainte-
nance studies.
Experimental agent vs placebo. Placebo-controlled stud-
ies are the standard for pivotal trials (figure 2A). We
propose several mitigating strategies to reduce the risk
of a disabling attack during placebo exposure, includ-
ing the following:
1. Liberal “escape” criteria in the event of treatment
failure (e.g., a single attack)
2. Ratio of subjects randomized to experimental treat-
ment vs placebo .1:1, reducing the odds that a
given patient will be assigned to the placebo group
3. Early recognition and uniform aggressive treat-
ment of attacks
4. Limited duration of placebo-controlled period
after which patients may receive active study drug
or empiric treatment
Figure 1 Study designs for treatment of attacks
(A) An experimental treatment (Expt Tx) is compared with placebo. At enrollment while in
relapse, a patient would either discontinue prior maintenance treatment (placebo-only
design) or not (placebo-controlled add-on). The study design could allow patients whose
initial treatment failed to cross over to the other treatment regimen. (B) An experimental
treatment is added to a standard regimen for management of an acute attack such as pulse
high-dose IV corticosteroids or plasma exchange (PLEX). The treatment may be used along
with the other empiric treatment from the outset or after a predefined period of initial treat-
ment in patients who have met failure criteria.
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Studies should be designed to observe the mini-
mum number of events necessary for achieving inter-
pretable and robust outcomes. Placebo-controlled
studies require fewer observed attacks to achieve ade-
quate statistical power than those comparing experi-
mental and an efficacious empiric therapy; however,
the risk of an attack for an individual patient may
be greater in a placebo-controlled than in an active
treatment comparator study. Placebo-controlled stud-
ies do not address superiority to current empiric treat-
ments that may be perceived as moderately effective
and relatively inexpensive. To address this concern,
one or more empiric therapy arms could be added
to a placebo-controlled study or subsequently evalu-
ated against an experimental agent that is proven to
be superior to placebo.
Add-on experimental agent vs placebo. Subjects are ran-
domized to experimental agent or placebo, while also
receiving a protocol-defined empiric regimen (figure
2B). Investigators may terminate patient participation
after a first on-study relapse. However, extended par-
ticipation in the randomized phase beyond the first
event is more acceptable to some stakeholders in an
add-on than in a pure placebo-controlled trial.
Extended participation increases power by allowing
each patient to contribute more than a single event.
Potential limitations include possible additive toxicity
of multiple agents and unwarranted attribution of
benefit to combined therapy when one agent might
be solely responsible. Effective empiric therapy may
also blur outcome specificity, thereby requiring
recruitment of additional subjects or observation of
more events than in a pure placebo trial. However,
the per-subject risk of an event may be lower. As
stated above, if a combination regimen proves effica-
cious, ensuing studies would be required to assess
the experimental agent alone (figure 2B) vs the
combination.
Experimental agent vs existing therapy. Direct comparison
of an investigational agent to an existing empiric
Figure 2 Phase IIb/III study designs for maintenance (attack prevention) treatment
(A) Patients are randomized to receive experimental treatment (Tx) or placebo. To minimize risk, liberal “escape” criteria are included in the protocol to
address on-study disease activity, such as occurrence of first attack. Those whose experimental therapy failed could be reassigned to empiric treatment or
an alternate treatment. (B) Patients are maintained on their existing regimen and randomized to receive experimental treatment or placebo as add-on
therapy. Inclusion of an optional experimental treatment alone arm (group C) might allow evaluation of potential interaction(s) between empiric and exper-
imental therapy. (C) Patients are randomized to receive either experimental or empiric treatment. (D) Patients are randomized to receive 1 of 2 existing
empiric therapies. This design is similar to design C, but 2 empiric treatments are compared directly. For all studies, interim analysis for futility and for
assessment of event rate and adjustment of sample size may be conducted with appropriate power correction.
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therapy circumvents concerns about pure placebo
exposure (figure 2C). Multiple options for empiric
therapy during the trial may be necessary, as subjects
may have failed one or more of comparator treat-
ments. A priori consensus of empiric therapy miti-
gates, but does not eliminate, unwanted variability in
the comparator. Active comparator studies require
large sample sizes to detect modest differences in effi-
cacy. Also, unrecognized deleterious effects of an
unproven comparator treatment may convolute eval-
uation of efficacy of the experimental treatment. A
variation of this approach is comparison of 2 empiric
therapies to evaluate superiority (figure 2D).
Outcome measures.Three study endpoints are poten-
tial measures of attack frequency or severity (table 3):
Time to first on-study event. Ending the randomized
phase at the first on-study attack mitigates the risk
of placebo exposure, allowing subjects access to alter-
native therapies when treatment fails. Time to first
attack is a continuous measure with inherent statisti-
cal advantages. Subjects experiencing an attack may
be eligible for an open-label investigational drug or
other empiric off-protocol treatment, but could no
longer contribute to efficacy evaluation. However,
withdrawal of patients after a first event sacrifices
information about efficacy and safety as compared
to assessment of the annualized relapse rate over the
entire observational period. Early relapses could result
in underestimation of efficacy for agents with delayed
effectiveness. To minimize the consequences of de-
layed effectiveness, a protocol might define a period
of initial treatment during which attacks do not qual-
ify as endpoints, either for primary or secondary anal-
ysis. Alternatively, all study participants could receive
corticosteroids for a defined period based on the phar-
macodynamics of the experimental agent to minimize
the risk of early relapse before the experimental agent
becomes effective. While any combination of treat-
ments could confound the interpretation of trial re-
sults, this approach equally distributes any beneficial
signal attributable to corticosteroid treatment among
subjects in all treatment limbs.
Annualized attack rate. This metric, a common pri-
mary outcome in MS clinical trials, annualizes net fre-
quency of all attacks. However, variation in the time
over which relapse rate is calculated is problematic
when dropout rates are high, and when they differ
between treatment groups.
Attack frequency/severity composite. Worsening in NMO
reflects the cumulative result of attack-related disabil-
ity. Although attacks are generally more severe than in
MS, milder attacks may also occur.45 Heightened
awareness of new or worsening symptoms in prospec-
tive clinical trials exaggerates the risk of recording
events that are not true attacks. For example, in the
recent open-label study of eculizumab, 2 on-study
events (back pain alone in one subject and a one-line
change of visual acuity in a second) were of equivocal
significance.21 Although experience with stratification
of attack severity is limited, a simple system for rating
optic nerve and spinal cord attacks has been applied
to retrospective studies.12 This strategy is similar to
well-accepted clinical scales used in MS46 and focuses
on visual, pyramidal, sensory, and sphincter functions
that are most consistently affected in NMO. Theo-
retically, each NMO attack could be rated based on
attack severity at nadir or after a fixed period of recov-
ery (e.g., 1 month), and a composite developed to
reflect attack frequency and severity (i.e., weighted
composite relapse severity/frequency score 5
P
attacki 3 severityi/time, i 5 1/n). Such an inte-
grated attack frequency and severity metric
would minimize the impact of mild equivocal events.
Alternatively, the distribution of attacks using a cat-
egorical prespecified scale (mild, moderate, severe) is
compared using nonparametric statistical tests to mit-
igate concerns surrounding variability of unvalidated
severity scoring scales.
A masked adjudication panel empowered to eval-
uate all relevant data in real time, including clinical,
laboratory, and imaging results, to independently
confirm attacks and grade their severity might reduce
study site–related variation in the application of an
attack frequency endpoint. Furthermore, an indepen-
dent adjudication panel would resolve potential
conflicts of site investigators who may be inclined
to interpret an equivocal event as an attack to facili-
tate treatment of the patient. The decisions of the
adjudication panel would not influence treatment
decisions for the trial subject, but could define the
primary endpoint.
OTHER ISSUES Phase of study. The phase of clinical
trial for an experimental NMO treatment relates to
antecedent experience. Safety profiles of repurposed
agents are better established than those of new thera-
pies developed specifically for NMO, possibly elimi-
nating the need for early-phase trials. Early-phase
clinical trials would be required for de novo drug
development; however, given the recent emphasis
on drug repurposing, phase II and III clinical trial
designs may be most relevant to planned NMO
clinical trials:
Phase IIa exploratory studies. Phase IIa or target
engagement studies are conducted for promising
agents for which adequate safety data are available
(figure 3). Patients enrolled in these studies typically
have active NMO that has failed one or more empiric
treatments. Dramatic reductions in attack frequency
compared with pretreatment in single-arm, open-
label studies (e.g., as revealed in patients treated with
rituximab [n 5 8],19 eculizumab [n 5 14],21 or
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tocilizumab [n 5 7]24) may portend favorable results
in controlled trials. However, “regression to the
mean” may be an alternative explanation, and decline
in event rates in placebo groups may exceed the dif-
ference between active and control groups.47 None-
theless, phase IIa exploratory studies may be useful for
screening novel NMO therapies in cohorts of 10 to
15 patients with recently active NMO whose other
treatments have failed. If safety criteria are met and
most subjects’ treatment has not failed, the agent may
be deemed “promising” and considered for phase IIb
and III studies. Sensitive biomarkers, if validated,
could accelerate drug development as has detection
of new MRI lesions for MS.
Phase IIb and III studies. Agents surviving the futility
criteria of phase IIa may be examined in subsequent
controlled studies to rigorously evaluate efficacy
(figure 2, A–D). First-line treatments should be inter-
rogated in relatively unselected populations represen-
tative of their intended use. However, second-line
treatments, including potent agents with less favorable
safety profiles, may be appropriate for severe or refrac-
tory NMO cohorts. Because no treatment is currently
proven to be efficacious in NMO, superiority rather
than noninferiority to the comparator is required.
Washout interval. Washout periods enhance the likeli-
hood that efficacy is attributed to the experimental
agent rather than to residual effects of prior treatment.
Patients with NMO receiving immunosuppressive
drugs may exhibit long-lasting carryover effects. For
example, rituximab-induced B-cell depletion may
persist for more than 1 year. However, patients are
potentially susceptible to relapse during washout
periods, negatively impacting safety and enrollment.
To address this concern, randomization may need to
be stratified based on prior treatment.
Masking. Definitive studies should be double-masked
by ensuring that the placebo has similar characteristics
(frequency and route of administration, color, etc.)
and by providing appropriate concomitant
medications to prevent infusion reactions. Where
adverse effects result in unavoidable unmasking, an
“evaluating” physician may be designated to assess
the primary outcome while another physician
evaluates safety, adverse effects, and decides whether
termination based on safety is necessary, a frequently
used strategy in MS trials.
Clinical trial pipeline. Innovative strategies for coordi-
nating NMO clinical trials to evaluate multiple agents
concurrently are desirable for phase I or IIa studies
(figure 3). In addition, if standardized inclusion cri-
teria and study procedures are adopted, control sub-
jects might be shared among multiple phase IIb and
III controlled clinical trials. Theoretically, this strat-
egy might provide a larger comparator, minimize
exposure to placebo, and enhance efficient use of
scarce patient resources. Moreover, subjects involved
in trials of “failed” therapeutic candidates could be
redirected into new studies through a streamlined
crossover mechanism to facilitate enrollment and
accrual. There are many hurdles to be overcome,
however. Diagnostic criteria continue to evolve and
have led to expansion of NMO disease spectrum.
Differences in inclusion and exclusion criteria based
on prior treatment and other subject antecedents vary
among studies and could affect the feasibility of
a common control group. Investigators, industry
sponsors, and regulators would need to be willing
to adopt standardized inclusion and exclusion crite-
ria and common study procedures across trials to
facilitate this initiative. However, it may be cost-
effective to all parties to facilitate multiple phase
IIa and possibly phase III studies proceeding
simultaneously. Thus, an NMO clinical trial
pipeline envisions a cooperative approach for
reducing risk to patients, optimizing enrollment,
offering patients greatest access to the most
promising drug candidates, and promoting long-
term resources (e.g., generation of clinical
information and biological sample resources for
investigational studies), ultimately advancing
NMO care.
Figure 3 Conceptual model of NMO clinical trial pipeline
Patients are enrolled in a staggered schedule based on agent availability. Some agents have
unacceptable adverse effects and are discontinued (agent A). Others fail prespecified futility
criteria and are not considered further (agent C). Indeterminate results may be addressed by
a longer period of observation and/or increased subject enrollment. Agents surviving the
futility criteria and demonstrating acceptable safety are then eligible for further evaluation
(agents B and D). If feasible, such a neuromyelitis optica (NMO) clinical trial “pipeline” might
be a pathway by which multiple agents can be evaluated in a way that directs subjects most
efficiently to potentially effective therapies.
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DISCUSSION NMO presents unique opportunities
and challenges for clinical trial design. Among the
most difficult aspects of such trials is implementation
of placebo-controlled studies, given the potential
severity of NMO attacks. Preventing attacks and
limiting their sequelae are highest priorities. Trial
designs must be acceptable to all stakeholders and
protect patient interests, while being informative
and robust. Careful definition of attack frequency
and severity, and discovery of surrogate efficacy
biomarkers should facilitate these goals. Innovative
approaches, such as shared placebo groups, may
expand and speed the investigative pipeline.
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